FarmaKology Newsletter - Issue #20
Oncora Medical is a digital health company bringing real world data to radiation oncology. Founded in 2014, Oncora builds intuitive software tools to collect and use real world clinical data to improve outcomes for cancer patients. We are driven by our shared vision of a future where every cancer patient is offered a custom-tailored treatment plan based on their predicted treatment response.
The Delhi High Court has allowed Alembic Pharmaceuticals and Natco Pharma to export sorafenib, an active ingredient in German pharma major Bayer’s cancer drug Nexavar, and rivaroxaban, the API in its blood thinner medicine Xarelto, for research and development purposes. The patent for Nexavar and Xarelto is scheduled to end next year.
Xynomic Pharmaceuticals Holdings, a clinical stage US-China oncology drug development company, announced that Xynomic Research Institute (XRI) has successfully designed a series of potent RET kinase inhibitors by computer-assisted drug design.
Immunotherapy developer Scancell announced the initiation of and further updates to the ‘SCIB1’ phase 2 trial in patients with metastatic melanoma also receiving the checkpoint inhibitor ‘pembrolizumab’ (Keytruda) on Monday.
Two rural Oregon pharmacies sold more opioid pills per county resident than 99.9% of other pharmacies in the country, recently released federal data show.